Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Patricia Brown

Physician Assistant Anchorage, AK Physician Assistant

NPI 1588878532 CMS profile 11182498

3340 Providence Dr, Ste 466, Anchorage, AK 99508

Open in the dashboard

General payments

$1,055

47 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patricia Brown of Anchorage, AK is reported in the CMS Open Payments database as having received $1,055 across 47 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14 1
2023 General $213 3
2022 General $476 23
2021 General $352 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patricia Brown
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Patricia Brown were reported at $14. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Patricia Brown Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $352 $132 $37–$438 $132
2022 $476 $155 $48–$522 $149
2023 $213 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $14 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $251 9 payments
  2. GlaxoSmithKline, LLC. $179 5 payments
  3. AbbVie, Inc. $88 4 payments
  4. E.R. Squibb & Sons, L.L.C. $88 5 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $70 3 payments
  6. Lilly USA, LLC $59 4 payments
  7. Philips Electronics North America Corporation $46 3 payments
  8. Alexion Pharmaceuticals, Inc. $44 3 payments
  9. TerSera Therapeutics LLC $43 1 payment
  10. Genzyme Corporation $30 2 payments
  11. Other $156 8 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,055 47 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $144 3 payments
  2. NUCALA $130 4 payments
  3. BREZTRI $107 6 payments
  4. UBRELVY $88 4 payments
  5. JARDIANCE Diabetes $70 3 payments
  6. STIOLTO RESPIMAT $70 3 payments
  7. SPIRIVA RESPIMAT $70 3 payments
  8. ELIQUIS $66 4 payments
  9. JARDIANCE Diabetes $59 4 payments
  10. TRULICITY $59 4 payments
  11. Other $430 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

298

Median for Physician Assistant: 241

Drug cost

$39,322

Median for Physician Assistant: $4,110

Branded share of claims

10.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 12 $23,672
Eliquis Apixaban Brand 20 $13,236
Atorvastatin Calcium Generic 59 $456
Losartan Potassium Generic 37 $330
Pravastatin Sodium Generic 15 $310
Trazodone Hcl Generic 24 $266
Esomeprazole Magnesium Generic 12 $236
Pantoprazole Sodium Generic 22 $195
Escitalopram Oxalate Generic 19 $152
Rosuvastatin Calcium Generic 16 $135

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record